CAMBRIDGE, Mass.--()--Verastem, Inc., (NASDAQ: VSTM) a clinical-stage biopharmaceutical company focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced that members of the management team will present at the BIO Investor Forum on October 9, 2012, at the Palace Hotel in San Francisco, CA.
The company presentation is at 8:30 am PT in the Presidio room and Jonathan Pachter, Ph.D., Verastem Vice President and Head of Research, will participate on a cancer stem cell panel from 10:30-11:25 am PT in the Twin Peaks room.
The panel will bring together scientific experts who are at the forefront of developing novel medicines targeting cancer stem cells. Dr. Pachter will discuss the potential of this approach to create durable clinical responses for patients with cancers that are typically refractory to conventional treatments. Verastem is translating basic science into clinical products based on the seminal publications in Cell and PNAS by Robert Weinberg, Ph.D., Verastem co-founder and chair of the Scientific Advisory Board.
A webcast of the company presentation can be accessed by visiting the investors section of the Company’s website at www.verastem.com. A replay of the webcast will be archived on the Verastem website for two weeks following the presentation date.
About Verastem, Inc.
Verastem, Inc. (NASDAQ: VSTM) is a clinical-stage biopharmaceutical company focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells. Cancer stem cells are an underlying cause of tumor recurrence and metastasis. Verastem is developing small molecule inhibitors of signaling pathways that are critical to cancer stem cell survival and proliferation: focal adhesion kinase (FAK), PI3K/mTOR and Wnt. For more information, please visit www.verastem.com.
Any statements in this press release about future expectations, plans and prospects for the Company constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements. The Company anticipates that subsequent events and developments will cause the Company’s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so.